Germany Biotechnology Market to Reach USD 91 Billion by 2032, Growing at a CAGR of 4.72% During 2026–2032

The Germany biotechnology market was valued at USD 63 billion in 2025 and is projected to reach USD 91 billion by 2032, growing at a CAGR of 4.72% during the forecast period 2026–2032. Growth is anchored in Germany's well-established biopharmaceutical manufacturing base, supported by sustained research investment and strong industry-academia collaboration.

Furthermore, biopharmaceutical companies are integrating artificial intelligence into routine drug discovery workflows. Merck KGaA partnered with Siemens in September 2025 to embed AI-driven discovery tools into the Luma platform, while Boehringer Ingelheim committed up to USD 15 million to Immunai in June 2026, reflecting AI's growing role in target identification and candidate selection.

Moreover, DNA Sequencing leads the technology segment with approximately 24% share, driven by Germany's Model Project Genome Sequencing, which integrated genome sequencing into statutory health insurance reimbursement from July 2024. In parallel, Reagents & Consumables remain the largest component segment at approximately 48% share, sustained by recurring demand from bioprocessing and diagnostic workflows.

Consequently, the competitive landscape remains moderately consolidated, with BioNTech SE, Boehringer Ingelheim GmbH, Thermo Fisher Scientific, Inc., Evotec SE, and Merck KGaA collectively holding approximately 38% of the total market share. As a result, continued biomanufacturing expansion and rising commercialization of cell and gene therapies are expected to sustain steady market growth through 2032, as stated in the recent report “Germany Biotechnology Market Analysis, 2026”.

Germany Biotechnology Market Highlights

The Germany Biotechnology Market was valued at USD 63 billion in 2025 and is projected to reach USD 91 billion by 2032, growing at a CAGR of 4.72% during 2026–2032.
The market is moderately consolidated, with the top five companies collectively accounting for approximately 38% of the total market share.
Reagents & Consumables represent the largest component segment, capturing approximately 48% of the market.
DNA Sequencing is the leading technology segment, accounting for approximately 24% of the market.